🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 53 Guangzhou 40 Beijing 33 Chengdu 13 Wuhan 10
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Peking Union Medical College Hospital276 Beijing Tiantan Hospital214 Cancer Institute and Hospital, Chinese Academy of Medical Sciences197 AstraZeneca183 Peking University People's Hospital158 Clear sponsor filter
Site location
Shanghai53 Guangzhou40 Beijing33 Chengdu13 Wuhan10
All 42 locations
Target enrolment
to

Trials with a site in Beijing

33 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study of BL-M08D in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors
NCT07780318Gastrointestinal Tumors, Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
60
Beijing
2026-09
Not yet open
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
NCT07641855Castration-resistant Prostate Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
180
Beijing, Shanghai
2026-09
Recruiting
A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast Cancer
NCT07678957Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
120
Beijing
2026-08-31
Recruiting
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT07753226Breast Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
39
Beijing
2026-08-18
Not yet open
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
NCT07744243Urological Cancer, Solid Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
30
Beijing
2026-08
Recruiting
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
NCT07606599Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
398
Hefei, Beijing
2026-07-07
Recruiting
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)
NCT07648914Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
446
Beijing
2026-07-06
Not yet open
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
NCT07545460Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
404
Beijing, Kunming
2026-07
Recruiting
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)
NCT07582315Biliary Tract Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
538
Beijing
2026-06-29
Recruiting
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
NCT07554456Esophageal Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2/3
90
Beijing
2026-06-09
Recruiting
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
NCT07518147Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
438
Beijing
2026-05-15
Recruiting
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
NCT07279428Gastrointestinal Tumors, Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
33
Beijing
2026-01-12
Not yet open
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
NCT06755242Gastrointestinal Tumors, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Beijing
2025-01
Recruiting
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
NCT06609187Breast Cancer, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
20
Beijing
2024-10-30
Recruiting
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
NCT06598787Recurrent Glioblastoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
20
Beijing
2024-10-17
Active, closed
A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)
NCT06382129Non-small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
698
Beijing
2024-05-17
Active, closed
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01)
NCT06343948HR+HER2- Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
383
Beijing
2024-04-24
Recruiting
A Study of BL-M05D1 in Patients With Locally Advanced or Metastatic Solid Tumors
NCT06349811Locally Advanced or Metastatic Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
30
Beijing
2024-04-19
Active, closed
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
NCT06304974Esophageal Squamous Cell Carcinoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3
497
Beijing
2024-03-19
Recruiting
A Study of BL-M07D1 in Patients With HER2-expressing Recurrent or Metastatic Gynecologic Malignancies
NCT06131450Gynecological Malignancies
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
138
Beijing
2024-02-29
Recruiting
A Study of BL-M07D1 in Patients With a Variety of Solid Tumors Including Locally Advanced or Metastatic HER2-positive/Low-expressing Urinary and Gastrointestinal Tumors
NCT06031584Her2-positive/Low-expression Urinary and Digestive Tract Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
42
Beijing
2024-01-19
Recruiting
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
NCT06008054Esophageal Cancer, Gastric Cancer, Colorectal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
376
Beijing
2023-11-16
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
NCT05990803Cervical Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
130
Beijing
2023-11-06
Recruiting
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies
NCT06066203Non-hodgkin's Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
40
Beijing
2023-11-01
Recruiting
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT05924750Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
130
Hefei, Beijing, Haerbin, Shenyang, Jinan, Shanghai, Chengdu, Tianjin
2023-08-02
Active, closed
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
NCT05485753Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
7
Beijing, Guangzhou, Zhengzhou
2023-02-10
Recruiting
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT05623982Non-hodgkin's Lymphoma
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1/2
40
Beijing, Haerbin, Qingdao
2022-09-26
Active, closed
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
NCT05393427Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
4
Beijing, Chongqing, Chengdu
2022-02-15
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
NCT05262491Gastrointestinal Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
96
Beijing, Nanchang, Jinan, Chengdu, Tianjin, Hangzhou
2022-02-14
Active, closed
SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.
NCT05022654Esophageal Squamous Cell Carcinomas
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
22
Beijing, Anyang, Luoyang, Xuzhou, Taiyuan, Suining
2021-12-13
Recruiting
A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors
NCT04794972Recurrent Glioma, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Guangzhou, Shenzhen, Xian, Chengdu
2021-04-14
Active, closed
A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
NCT04606472Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
60
Beijing, Chongqing, Xiamen, Zhengzhou, Wuhan, Shanghai, Chengdu
2020-11-10
Active, closed
Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
NCT04606433Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
47
Hefei, Beijing, Chongqing, Guangzhou, Changsha, Shanghai, Tianjin, Hangzhou
2020-11-04
Rows per page Showing 1–33 of 33
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 33 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

20 of the 33 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 33 studies
PhaseStudiesRecruitingShare
Phase 112736.4%
Phase 38424.2%
Phase 1/26418.2%
Phase 25415.2%
Phase 2/3216.1%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.3320
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.